HALOHIGH SIGNALFINANCIAL10-K

HALO's stockholders' equity collapsed 86.6% from $363.8M to $48.8M while debt surged 42.3% to $2.1B, creating a severely deteriorated balance sheet despite strong revenue growth.

The massive destruction of shareholder equity combined with substantial debt increases signals serious financial distress or a major corporate transaction that has fundamentally weakened the company's capital structure. While revenue doubled, the dramatic balance sheet deterioration suggests investors should be deeply concerned about the company's financial stability and leverage position.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

HALO presents a paradoxical financial picture with revenue surging 86.3% to $121.7M and operating cash flow growing 36% to $651.6M, indicating strong operational performance. However, the balance sheet tells a troubling story with stockholders' equity cratering 86.6% to just $48.8M while total debt ballooned 42.3% to $2.1B, creating an extremely leveraged capital structure. The company also ramped up share buybacks by 37% to $342.4M, which may have contributed to the equity destruction alongside the debt increases, suggesting either aggressive financial engineering or distressed capital allocation decisions.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-86.6%
$363.8M$48.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Revenue
P&L
+86.3%
$65.3M$121.7M

Strong top-line growth of 86.3% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+77.7%
$3.5M$6.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
+47.9%
$288.2M$426.3M

Receivables surged 47.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
+45.7%
$1.7B$2.5B

Liabilities grew 45.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
+42.3%
$1.5B$2.1B

Debt increased 42.3% — substantial leverage increase; assess whether deployed for growth or covering losses.

Share Buybacks
Cash Flow
+36.9%
$250.0M$342.4M

Share repurchases increased 36.9% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
+36%
$479.1M$651.6M

Operating cash flow surged 36% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
-34.8%
$10.7M$7.0M

Capex reduced 34.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
+34.2%
$154.3M$207.1M

SG&A up 34.2% — significant increase in sales or administrative costs, monitor impact on operating leverage.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
The number of outstanding shares (in thousands) of the registrant s common stock, par value $0.001 per share, was 118,017 as of February 10, 2026.
Workforce reduction at federal agencies and changes in United States ( U.S.
) trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.
s two wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG, Halozyme Hypercon, Inc., Halozyme Hypercon Inc.
s wholly-owned subsidiary, Elektrofi Security Corp., and Halozyme Surf Bio, Inc.
+7 more — sign up free →
REMOVED
The number of outstanding shares (in thousands) of the registrant s common stock, par value $0.001 per share, was 123,153 as of February 11, 2025.
s wholly-owned subsidiaries, Antares Pharma IPL AG and Antares Pharma AG.
We currently earn royalties from the sales of nine commercial products including sales of five commercial products from the Roche collaboration and one commercial product from each of the Takeda, Janssen, argenx and BMS collaborations.
We have development programs including our auto-injectors with Idorsia Pharmaceuticals Ltd.
Our principal offices and research facilities are located at 12390 El Camino Real, San Diego, CA 92130.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →